Antibody‑drug conjugates (ADCs) dominated ESMO 2025 sessions, with presentations showing activity across urothelial, breast and ovarian cancers and renewed emphasis on combination regimens. BioCentury and conference coverage highlighted trials pairing ADCs with PD‑1 inhibitors or chemotherapies, as well as industry deals that underscore commercial interest in next‑generation payloads and linkers. Speakers and corporate symposia, including AstraZeneca and Merck appearances, framed the 2020s as the “decade of ADCs,” noting that strategic combinations and improved targeting are expanding clinical utility. Trial readouts at the meeting are accelerating registrational plans for several ADC programs and are prompting real‑time partnership and licensing activity.